Back to search results

Susan G. Komen's ShareForCures for Breast Cancer Research

This study, called ShareForCures, is creating a large collection of health information from people with breast cancer across the United States. The goal is to gather diverse data, including from groups often underrepresented in research, to help scientists better understand breast cancer. By making this information available, researchers hope to improve breast cancer care for everyone. You can join if you are at least 18 years old (or 19 in Alabama and Nebraska, 21 in Mississippi and Pennsylvania) and have been diagnosed with breast cancer. The study aims to engage participants, integrate their data, and facilitate scientific research over 10 years.

Study design
This is an observational study aiming to enroll up to 200,000 participants. It is a community-based participatory research registry.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participant data will be integrated and used for scientific research for up to 10 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05654246

Susan G. Komen's ShareForCures

Recruiting
Not specifiedAges 18+Observational
Susan G. Komen Breast Cancer Foundation
~200,000 participants
Updated 2026-03-06 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Engage participants representative of the United States breast cancer patient population in ShareForCures.
Measured over 10 years
+2 more outcomes measured

Conditions

Breast Cancer

Explore related trials

Breast Carcinoma

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Jerome Jourquin, Ph.D., M.S. · PRINCIPAL_INVESTIGATOR · Susan G. Komen

Who to contact

Jerome Jourquin, Ph.D., M.S.
[email protected]
1-877-465-6636
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Individuals must be at least 18 years old. (Individuals in Alabama and Nebraska must be over 19 and individuals in Mississippi and Pennsylvania must be over 21 to participate).
Individuals must have been diagnosed with cancer originating (or is suspected to originate) from the breast.
Individuals must be currently residing in the United States or a territory of the United States.
Individuals must be able to read and understand English.

Exclusion

Individuals under the age of 18 years. (Individuals in Alabama and Nebraska under 19 and individuals in Mississippi and Pennsylvania under 21 are not eligible to participate).
Individuals without a diagnosis of breast cancer.
Individuals who are not residing in the United States or a territory of the United States.
Individuals unable to read and understand English.

What this trial measures

  • Engage participants representative of the United States breast cancer patient population in ShareForCures.10 years

    Enroll and engage up to 200,000 people, who have been diagnosed with breast cancer, reflecting the diversity of breast cancer survivors within the United States, to participate in the registry as our partners in research.

  • Integrate participant data into ShareForCures.10 years

    Collect and curate a rich scope of participant data from a variety of sources (including participant-provided information, clinical records, and linkage to other existing datasets) and biospecimens to create a comprehensive, longitudinal database.

  • Facilitate scientific research using ShareForCures data.10 years

    Make deidentified data available to researchers for scientific discoveries, including research that may lead to new knowledge about breast cancer and advances in patient care and outcomes.